Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure
- PMID: 1929334
- PMCID: PMC245229
- DOI: 10.1128/AAC.35.8.1616
Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure
Abstract
The removal of imipenem and cilastatin by hemodialysis was studied in 14 (for imipenem) and 6 (for cilastatin) subjects. Following intravenous infusion of imipenem and cilastatin at a combined concentration of 10 mg/kg of body weight, drug levels in plasma were determined serially during off- and on-hemodialysis periods, which were 2 and 4 h, respectively. The biexponential decay of the drug levels in plasma was evident in each subject for both imipenem and cilastatin. Hemodialysis accelerated the elimination of both imipenem and cilastatin: the mean elimination-phase half-life of imipenem was shortened from 200 to 78 min, and that of cilastatin was shortened from 445 to 115 min. Hemodialysis clearance of imipenem and cilastatin was calculated by five different methods, each with intrinsic assumptions. The mean hemodialysis clearance of imipenem was estimated to be 74.08 +/- 13.29 ml/min, and that of cilastatin was estimated to be 65.0 +/- 8.6 ml/min, after consideration of various methodological limitations. It was estimated that in a hypothetical anephric patient weighing 60 kg, a 4-h hemodialysis treatment would remove 54.8% of the imipenem and 62.9% of the cilastatin present in the body at the start of dialysis.
Similar articles
-
[Clinical pharmacokinetics of an imipenem-cilastatin combination].Presse Med. 1990 Apr 4;19(13):598-605. Presse Med. 1990. PMID: 2139939 French.
-
Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.J Antimicrob Chemother. 1991 Feb;27(2):225-32. doi: 10.1093/jac/27.2.225. J Antimicrob Chemother. 1991. PMID: 2055813
-
Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.Clin Nephrol. 1994 Sep;42(3):193-7. Clin Nephrol. 1994. PMID: 7994939
-
An overview of the pharmacology of imipenem/cilastatin.J Antimicrob Chemother. 1986 Dec;18 Suppl E:79-92. doi: 10.1093/jac/18.supplement_e.79. J Antimicrob Chemother. 1986. PMID: 3546249 Review.
-
Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1992 Sep;44(3):408-44. doi: 10.2165/00003495-199244030-00008. Drugs. 1992. PMID: 1382937 Review.
Cited by
-
Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.Intensive Care Med. 1995 Apr;21(4):348-51. doi: 10.1007/BF01705414. Intensive Care Med. 1995. PMID: 7650258
-
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.Clin Pharmacokinet. 2006;45(8):755-73. doi: 10.2165/00003088-200645080-00001. Clin Pharmacokinet. 2006. PMID: 16884316 Review.
-
Optimization of anti-infective dosing regimens during online haemodiafiltration.Clin Kidney J. 2017 Apr;10(2):282-290. doi: 10.1093/ckj/sfx009. Epub 2017 Mar 29. Clin Kidney J. 2017. PMID: 28396747 Free PMC article.
-
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.BMC Nephrol. 2024 Feb 27;25(1):73. doi: 10.1186/s12882-024-03469-2. BMC Nephrol. 2024. PMID: 38413858 Free PMC article.
-
Comparative pharmacokinetics of the carbapenems: clinical implications.Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002. Clin Pharmacokinet. 2000. PMID: 11020134 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases